
Assistant Professor/Group Leader At the interface of immunology and disease, developing therapies & vaccines @MGH @HMS @VICatMGH @mgh_transplant
Boston, MA
Joined December 2008
- Tweets1.3K
- Following1.4K
- Followers400
- Likes4.4K
Patrick Reeves retweeted
Excited to share our new @brooks_lab paper in @cellpressblue! We discovered two mechanisms by which interferons suppress T cells, revealing a new layer of immune regulation with exciting implications for #immunotherapy!
tinyurl.com/a8jpue2w
@UHN @pmcancercentre @thePMCF
Patrick Reeves retweeted
The blood-brain barrier imports diverse neuroprotective proteins through pathways impaired early in Alzheimer’s disease models. @CellCellPress cell.com/cell/fulltext/S0092…
Patrick Reeves retweeted
Spatiotemporal dynamics of adoptively transferred stem-like CD8+ T cells in the tumor microenvironment following vaccination
cell.com/cell-reports-medici…
@CellRepMed
Patrick Reeves retweeted
大腸がんで、抗PD-1単独では不十分なTH1様CD4+T細胞応答を、抗OX40併用により末梢の幹細胞様前駆細胞から増幅し、腫瘍内TH1様細胞への移行、CD8+T細胞応答、マクロファージ再構築を強めて免疫療法を高めることを示した論文がScience誌に発表されました。
science.org/doi/10.1126/scie…
Patrick Reeves retweeted
Friends, it is a good time to get yourself a liquid handling robot
AI agents enter the wet lab.
In new @Nature N&V article, I discuss recent advances in agents running automated labs and ideas on how to make these systems more reliable. nature.com/articles/d41586-0…
Patrick Reeves retweeted
Check out our new paper!
Control of M. tuberculosis infection requires CD28 to generate lung-homing T cells and CTLA-4 to limit immunopathology from @danielleobarber and colleagues: mucosalimmunology.org/articl…
Patrick Reeves retweeted
Eight experts in T cell exhaustion, including I3H Director @EJohnWherry, weigh in on what’s known and what’s still debated about self-renewing PD1+TCF1+TOX+ progenitor exhausted CD8+ T cells in a new @NatRevImmunol Viewpoint: go.nature.com/4dZPpRz
Patrick Reeves retweeted
Choose to work in a lab that values both “day science” and “night science”: creativity, openness, and the freedom to explore ideas, alongside disciplinary excellence, reproducibility and scholarship. Inspiration flows from both solitary focus and lively exchange. We celebrate both the joy and the occasional disorientation of discovery together.
@KleinLabHMS kleinlab.bio/lab-culture
Patrick Reeves retweeted
🦉 When Immunotherapy Makes Metastasis Worse
PD-1 blockade is designed to restore T-cell activity. But what happens when tumor cells cannot present the antigens those T cells need to recognize?
In a humanized mouse model of MHC-I-deficient head and neck cancer, pembrolizumab failed to control primary tumors and increased liver metastases. Tumors also showed fewer CD8+ T cells, activated T cells and dendritic cells.
Restoring MHC-I improved immune responses to PD-1 blockade in cell cultures, particularly with LSD1 inhibition.
The finding raises a concern beyond conventional drug resistance: checkpoint blockade may coincide with worse metastatic behavior when antigen presentation is defective.
But the evidence is preclinical. The study did not establish how pembrolizumab increased metastasis, and the MHC-I-deficient and competent mouse models were not directly matched.
MHC-I status may therefore matter not only for predicting treatment failure, but also for investigating unexpected progression during checkpoint therapy.
#immunotherapy #T_cell #CAR_T
nature.com/articles/s41392-0…
Patrick Reeves retweeted
How does our history of influenza infections shape the ability of CD8+ T cells to recognize new viral variants? Our new paper in @CellReports examines these questions using influenza-specific CD8+ T cells! 🧵⬇️ (1/12)
cell.com/cell-reports/fullte…
Patrick Reeves retweeted
Our new work using virus-specific T cells as biosensors in Long COVID. These data point to viral persistence detected by T cells and some level of T cell exhaustion. Excellent work by @markmpainter biorxiv.org/content/10.64898…
Patrick Reeves retweeted
I’m excited to share MeRN, our new method for inferring single-cell metabolic states from transcriptomic data that enables the discovery of metabolic data-driven pathways! 🧵 1/
Preprint: biorxiv.org/content/10.64898…
GitHub: github.com/wagnerlab-berkele…
Tutorial: wagnerlab-berkeley.github.io…
After many years of effort, deliberation, excitement, angst, joy, and Wednesday afternoon lab lunches, our group's first manuscript on cachexia, led by Venise Jan Castillon, Amy Xie, and really our whole lab nature.com/articles/s41591-0… @NatureMedicine
Patrick Reeves retweeted
Specificity defines adaptive immunity. Yet we've never comprehensively tested how differences in the epitopes human T cells recognize correlate with disease risk. I explore why in this review & argue we now have the tools to change it 🧵1/12 onlinelibrary.wiley.com/doi/…
Patrick Reeves retweeted
CytoVI is finally out in @naturemethods! We introduce our first deep generative model built for immunologists working with cytometry data to mitigate some of the most pressing limitations of the technology! Grateful for the fantastic collaboration with @YosefLab & @IdoAmitLab
Different panels. Different technologies. Can we bring flow cytometry into biology’s AI revolution?
Introducing CytoVI in @NatureMethods: linking cytometry & single-cell genomics to predict missing markers and reveal disease-associated cell states.🧵(1/15)
doi.org/10.1038/s41592-026-0…
Tumor cells are literally handing their mitochondria to the T cells meant to kill them.
The T cells can't digest them, so the cancer's mitochondria take over, the T cells go senescent, and killing stops. Researchers spotted it because the T cells carried mitochondrial DNA mutations identical to those of the tumor.
Patients whose tumors had those mutations did worse on immunotherapy.
Patrick Reeves retweeted
1/12
We are excited to share our new preprint on bioRxiv: "Spatially Resolved Multimodal Hallmarks of Response to Neoadjuvant Immunotherapies in the Melanoma Ecosystem in 2D and 3D." 🧵
biorxiv.org/content/10.64898…
@Zliu1218, Jeff Chuang Lab | @MoffittNews @JAXcancercenter
Patrick Reeves retweeted
Replying to @PeiLingChen_MD @Zliu1218 @MoffittNews @JAXcancercenter @vizgen_inc @alpenglowbio @USouthFlorida @DrJamesMule @VernSondakMD @song_xiaofei @MarkowitzLab @JiangHe_PhD @RederredeR
11/12
3D light-sheet imaging and CODA 3D reconstruction show germinal centers that look separate in 2D are often interconnected tunnels in 3D, raising real questions about whether single-section histopathology adequately captures neoadjuvant ICB response assessment.
Patrick Reeves retweeted
Insane paper alert!
Interferon is the one therapy that can actually deplete the mutant stem cells in myeloproliferative neoplasms, the blood cancers where the marrow keeps overproducing one lineage or another. The standard explanation for how it works was fairly mechanical. It pushes the mutant cells into the cell cycle, they divide, and eventually they exhaust or lose ground. Clean enough to teach. Lama et al. pulls it apart, and it can do that because of a set of single-cell methods that read out the mutation, the transcriptome, the surface proteins and the chromatin in the same cell, so the healthy stem cells sit inside the same patient as a built-in control, right next to their mutant neighbors.
What they see is that interferon does not do one thing to a stem cell, it does two opposite things at once. Part of the stem pool is driven into an inflammatory myeloid progenitor state nobody had really described before, running on AP-1 and NF-κB. Another part is pushed toward lymphoid output. That lymphoid arm is easy to overlook, but it seems to be doing the clinical work, offsetting the myeloid overproduction that defines the disease, which is likely why counts normalize even in patients whose mutant fraction barely moves.
Interestingly, the result that carries the paper is a negative one. If fitness ran on proliferation, the clones cycling fastest under interferon should be the ones whose fate you could predict. But the mutant cells cycled faster than the healthy ones throughout, before treatment and during it, and that gap predicted nothing about which clones expanded and which collapsed. What predicted it was whether a clone would follow that inflammatory myeloid path out of the stem state. The ones that resisted held on or grew. The ones that went along got cleared.
So the drug is not really wearing the clone down. It is holding open an exit from the stem cell state, and resistance amounts to declining to take it. The mutations tilt the cell's transcription-factor wiring, PU.1 in particular, so mutant and healthy cells read the same interferon signal differently, and the mutant ones tend to sit tighter in the stem compartment…and the same resistance signature turns up in DNMT3A clonal hematopoiesis, so it is probably not tied to one mutation or one disease. If a clone survives by refusing to differentiate, killing it is beside the point. You would have to take the exit away, so it has to leave the stem state whether it resists or not, and I don't know what that looks like yet, or how much of this same quiet sorting runs in ordinary aging marrow where no one is being treated at all.
@AnnaEnim @landau_lab and many more rockstars!
#MyeloproliferativeNeoplasms #Hematology #StemCellBiology #SingleCell #Interferon
Nature Genetics, doi.org/10.1038/s41588-026-0…































